Physician profile
Kyle Cheng
NPI 1306103064
$19,986.61
in general payments reported to CMS, 2019-2025
21 companies · $3,118 in 2025
The $3,118 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $1,535 · 2021: $6,207 · 2022: $1,513 · 2023: $3,952 · 2024: $3,504 · 2025: $3,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,435 · Food and Beverage: $3,862 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,435.00 |
| Food and Beverage | $3,861.88 |
| Education | $277.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,228.88 | 2021 | |
| Ucb, INC. | $2,813.87 | 2019-2025 | Bimzelx |
| Abbvie INC. | $2,465.73 | 2021-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $2,395.60 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $2,355.34 | 2024-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $2,167.85 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $876.16 | 2024-2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $369.05 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $261.26 | 2021-2025 | |
| Incyte Corporation | $216.03 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $138.83 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $136.21 | 2022-2025 | |
| Blueprint Medicines Corporation | $131.05 | 2025 | Ayvakit |
| Lilly USA, LLC | $122.31 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $106.35 | 2024-2025 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $73.20 | 2024 | |
| Leo Pharma INC. | $52.92 | 2025 | Anzupgo, Adbry |
| Amgen INC. | $29.21 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.07 | 2019 | |
| Organon LLC | $15.17 | 2025 | Vtama |
| Ani Pharmaceuticals, INC. | $13.52 | 2025 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.